BRPI0817265A2 - Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada - Google Patents

Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada

Info

Publication number: BRPI0817265A2
Authority: BR; Brazil
Prior art keywords: rna; rna molecule; vaccine; isolated; molecule
Prior art date: 2007-09-28

Application number

BRPI0817265-0A

Other languages

English (en)

Inventor

Josef Thalhamer

Richard Weiss

Sandra Scheiblhofer

Angelika Frühwirth

Original Assignee

Biomay Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-28

Filing date

2008-09-29

Publication date

2015-06-16

2008-09-29 Application filed by Biomay Ag filed Critical Biomay Ag

2015-06-16 Publication of BRPI0817265A2 publication Critical patent/BRPI0817265A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Zoology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Virology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0817265-0A 2007-09-28 2008-09-29 Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada BRPI0817265A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07450169A EP2042193A1 (en)	2007-09-28	2007-09-28	RNA Vaccines
PCT/EP2008/063035 WO2009040443A1 (en)	2007-09-28	2008-09-29	Rna vaccines

Publications (1)

Publication Number	Publication Date
BRPI0817265A2 true BRPI0817265A2 (pt)	2015-06-16

Family

ID=38847002

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0817265-0A BRPI0817265A2 (pt)	2007-09-28	2008-09-29	Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada

Country Status (11)

Country	Link
US (3)	US20110033416A1 (pt)
EP (2)	EP2042193A1 (pt)
JP (1)	JP5535920B2 (pt)
CN (1)	CN101827606B (pt)
AU (1)	AU2008303483B2 (pt)
BR (1)	BRPI0817265A2 (pt)
CA (1)	CA2700604C (pt)
DK (1)	DK2200646T3 (pt)
ES (1)	ES2434221T3 (pt)
PL (1)	PL2200646T3 (pt)
WO (1)	WO2009040443A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2042193A1 (en)	2007-09-28	2009-04-01	Biomay AG	RNA Vaccines
WO2010018384A1 (en)	2008-08-15	2010-02-18	Circassia Limited	T-cell antigen peptide from allergen for stimulation of il-10 production
JP5746053B2 (ja)	2009-02-05	2015-07-08	サーカッシアリミテッド	ワクチン用ペプチド
CA2804396C (en)	2010-07-06	2021-06-29	Novartis Ag	Liposomes with lipids having an advantageous pka-value for rna delivery
LT3243526T (lt)	2010-07-06	2020-02-10	Glaxosmithkline Biologicals S.A.	Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
SI2591114T1 (sl)	2010-07-06	2016-10-28	Glaxosmithkline Biologicals S.A.	Imunizacija velikih sesalcev z majhnimi odmerki RNA
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
PT2611461T (pt)	2010-08-31	2022-05-26	Glaxosmithkline Biologicals Sa	Lipossomas peguilados para entrega de arn codificador de imunogénio
DE19177059T1 (de)	2010-10-01	2021-10-07	Modernatx, Inc.	N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
US20140030292A1 (en)	2010-10-11	2014-01-30	Novartis Ag	Antigen delivery platforms
DE12722942T1 (de)	2011-03-31	2021-09-30	Modernatx, Inc.	Freisetzung und formulierung von manipulierten nukleinsäuren
EP3332802A1 (en)	2011-07-06	2018-06-13	GlaxoSmithKline Biologicals SA	Immunogenic combination compositions and uses thereof
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
KR20190099538A (ko)	2011-10-03	2019-08-27	모더나 세라퓨틱스, 인코포레이티드	변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP2791160B1 (en)	2011-12-16	2022-03-02	ModernaTX, Inc.	Modified mrna compositions
CA2868393A1 (en)	2012-04-02	2013-10-10	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2876824C (en)	2012-06-15	2020-07-21	Immunomic Therapeutics, Inc.	Nucleic acids for treatment of allergies
SI2922554T1 (sl)	2012-11-26	2022-06-30	Modernatx, Inc.	Terminalno modificirana RNA
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt)	2013-10-03	2017-09-12	Moderna Therapeutics Inc	polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
FI3981437T3 (fi)	2014-04-23	2025-01-10	Modernatx Inc	Nukleiinihapporokotteita
JP6088584B2 (ja) *	2015-06-15	2017-03-01	イミュノミックセラピューティックス，インコーポレイテッドＩｍｍｕｎｏｍｉｃＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	アレルギー治療のための核酸
KR102259447B1 (ko) *	2016-12-27	2021-06-02	고쿠리츠다이가쿠호우진 도쿄다이가쿠	mRNA 의 기능화 방법
WO2019216394A1 (ja) *	2018-05-11	2019-11-14	アステラス製薬株式会社	ダニアレルギー治療のための核酸
EP4134674A1 (en)	2021-08-13	2023-02-15	Euroimmun Medizinische Labordiagnostika AG	Methods and reagents for detecting an antibody to a ses ipr-10 allergen
CN114262378B (zh) *	2021-12-20	2023-03-24	南京诺唯赞生物科技股份有限公司	一种omt的单克隆抗体及其制备方法
JP2025508467A (ja)	2022-02-24	2025-03-26	アイオーバイオテックエーピーエス	癌治療のヌクレオチド送達
EP4520345A1 (en)	2023-09-06	2025-03-12	Myneo Nv	Product

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5830463A (en) *	1993-07-07	1998-11-03	University Technology Corporation	Yeast-based delivery vehicles
FR2715847B1 (fr)	1994-02-08	1996-04-12	Rhone Poulenc Rorer Sa	Composition contenant des acides nucléiques, préparation et utilisations.
FR2730637B1 (fr)	1995-02-17	1997-03-28	Rhone Poulenc Rorer Sa	Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US20030202980A1 (en) *	1995-12-29	2003-10-30	Caplan Michael J.	Methods and reagents for decreasing clinical reaction to allergy
SE9903950D0 (sv)	1999-10-29	1999-10-29	Pharmacia & Upjohn Diag Ab	Non-anaphylactic forms of grass pollen allergen and their use
US20050154189A1 (en) *	2000-06-23	2005-07-14	Maxygen Inc	Novel co-stimulatory molecules
CU22983A1 (es) *	2002-05-08	2004-09-09	Inst Finlay	Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
EP1545625B1 (en) *	2002-06-07	2011-08-24	Kentucky Bioprocessing, LLC	Flexible vaccine assembly and vaccine delivery platform
DK1440979T3 (da)	2003-01-21	2005-12-19	Biomay Prod & Handel	Fremgangsmåde til fremstillingen af hypoallergene mosaikproteiner
DE102004042546A1 (de) *	2004-09-02	2006-03-09	Curevac Gmbh	Kombinationstherapie zur Immunstimulation
US7767212B2 (en) *	2005-03-18	2010-08-03	Cytos Biotechnology Ag	CAT allergen conjugates and uses thereof
EP2042193A1 (en)	2007-09-28	2009-04-01	Biomay AG	RNA Vaccines

2007
- 2007-09-28 EP EP07450169A patent/EP2042193A1/en not_active Withdrawn
2008
- 2008-09-29 PL PL08804887T patent/PL2200646T3/pl unknown
- 2008-09-29 AU AU2008303483A patent/AU2008303483B2/en active Active
- 2008-09-29 US US12/680,354 patent/US20110033416A1/en not_active Abandoned
- 2008-09-29 BR BRPI0817265-0A patent/BRPI0817265A2/pt not_active Application Discontinuation
- 2008-09-29 CA CA2700604A patent/CA2700604C/en active Active
- 2008-09-29 DK DK08804887.1T patent/DK2200646T3/da active
- 2008-09-29 ES ES08804887T patent/ES2434221T3/es active Active
- 2008-09-29 JP JP2010526322A patent/JP5535920B2/ja active Active
- 2008-09-29 WO PCT/EP2008/063035 patent/WO2009040443A1/en active Application Filing
- 2008-09-29 EP EP08804887.1A patent/EP2200646B1/en active Active
- 2008-09-29 CN CN200880109057.8A patent/CN101827606B/zh active Active
2013
- 2013-09-13 US US14/026,436 patent/US20140134129A1/en not_active Abandoned
2017
- 2017-01-20 US US15/410,807 patent/US11020477B2/en active Active

Also Published As

Publication number	Publication date
AU2008303483B2 (en)	2013-10-31
US11020477B2 (en)	2021-06-01
CN101827606A (zh)	2010-09-08
AU2008303483A1 (en)	2009-04-02
JP5535920B2 (ja)	2014-07-02
JP2010540500A (ja)	2010-12-24
CA2700604A1 (en)	2009-04-02
PL2200646T3 (pl)	2014-01-31
EP2042193A1 (en)	2009-04-01
CN101827606B (zh)	2017-08-22
US20110033416A1 (en)	2011-02-10
EP2200646B1 (en)	2013-08-07
EP2200646A1 (en)	2010-06-30
WO2009040443A1 (en)	2009-04-02
US20140134129A1 (en)	2014-05-15
ES2434221T3 (es)	2013-12-16
US20170136121A1 (en)	2017-05-18
CA2700604C (en)	2016-04-26
DK2200646T3 (da)	2013-10-21

Publication	Publication Date	Title
BRPI0817265A2 (pt)	2015-06-16	Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
BRPI0813627A2 (pt)	2014-12-23	Peptídio antimicrobiano, composições e métodos de uso
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
SMT201600388B (it)	2017-03-08	Ligandi leganti opsina, composizioni e metodi d'uso
BRPI1005322A2 (pt)	2019-09-24	anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0819299A2 (pt)	2014-10-07	Uso de composição, e, composição contendo proteína
BRPI0813770A2 (pt)	2014-12-30	Composição, e, uso de uma composição
BRPI0811635A2 (pt)	2014-11-11	Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
DK1926496T3 (da)	2013-09-30	PCV-2-vaccine
BRPI0917315A2 (pt)	2015-11-17	anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0918502A2 (pt)	2015-12-01	aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BRPI0822104A2 (pt)	2014-10-07	Composições antimicrobianas e métodos para o uso das mesmas
DK1968631T3 (da)	2015-06-15	Vaccine
DK1984009T3 (da)	2013-01-28	Farmaceutiske sammensætninger med forbedret stabilitet
BRPI0821668A2 (pt)	2015-06-16	Uso
BRPI0618904A2 (pt)	2016-09-13	composto, composição farmacêutica, e, uso do composto
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
DK1940467T3 (da)	2017-02-13	Lægemiddelsammensætning med langvarig frigivelse
BRPI0815190A2 (pt)	2015-03-31	Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0816350A2 (pt)	2015-02-24	Composições orais, produtos e métodos de uso
BRPI0907453A2 (pt)	2015-07-14	Compostos, uso e preparação dos mesmos
BRPI0915120A2 (pt)	2016-07-26	composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0812909A2 (pt)	2014-12-09	Derivados de guanina policíclica e métodos de uso dos mesmos.
BRPI0914793A2 (pt)	2015-08-04	Composição, e, uso de uma composição

Legal Events

Date	Code	Title	Description
2016-12-20	B25A	Requested transfer of rights approved	Owner name: BIONTECH RNA PHARMACEUTICALS GMBH (DE)
2017-03-28	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-11-07	B07E	Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-11-06	B07A	Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
2019-12-10	B07A	Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
2021-03-09	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-05-25	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL